DrugPatentWatch Database Preview
Drugs in Development Information for Relacorilant
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for Relacorilant?
Relacorilant is an investigational drug.
There have been 8 clinical trials for Relacorilant.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2018.
The most common disease conditions in clinical trials are Syndrome, Cushing Syndrome, and Carcinoma. The leading clinical trial sponsors are Corcept Therapeutics, University of Chicago, and National Cancer Institute (NCI).
There are eight US patents protecting this investigational drug and forty-eight international patents.
Summary for Relacorilant
| US Patents | 8 |
| International Patents | 48 |
| US Patent Applications | 13 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2018-10-01) |
| Vendors | 6 |
Recent Clinical Trials for Relacorilant
| Title | Sponsor | Phase |
|---|---|---|
| Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Corcept Therapeutics | Phase 2 |
| Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer | Corcept Therapeutics | Phase 1 |
| Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for Relacorilant
Top disease conditions for Relacorilant
Top clinical trial sponsors for Relacorilant
US Patents for Relacorilant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Relacorilant | Start Trial | Glucocorticoid receptor modulators to treat pancreatic cancer | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| Relacorilant | Start Trial | Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| Relacorilant | Start Trial | Glucocorticoid receptor modulators to treat cervical cancer | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| Relacorilant | Start Trial | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| Relacorilant | Start Trial | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| Relacorilant | Start Trial | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (Menlo Park, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Relacorilant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Relacorilant | Australia | 2017323636 | 2036-09-09 | Start Trial |
| Relacorilant | Brazil | 112019004322 | 2036-09-09 | Start Trial |
| Relacorilant | Canada | 3034114 | 2036-09-09 | Start Trial |
| Relacorilant | China | 109689044 | 2036-09-09 | Start Trial |
| Relacorilant | European Patent Office | 3509584 | 2036-09-09 | Start Trial |
| Relacorilant | Israel | 265217 | 2036-09-09 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
